Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non–Small-Cell Lung Cancer: A Single-Center Evaluation

Iguchi, Toshihiro; Hiraki, Takao; Matsui, Yusuke; Mitsuhashi, Toshiharu; Katayama, Norihisa; Katsui, Kuniaki; Soh, Junichi; Sakùrai, Jun; Gobara, Hideo; Toyooka, Shinichi; Kanazawa, Susumu

doi:10.1016/j.jvir.2019.11.035

Cited by 23 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…-SABR worse than SLR (HR = 1.60; P < 0.001) Subgroup analysis (4 of 12 studies), there were no significant differences in terms of 3-year survival, OS and 3-year locorregional control SABR shows a local control rate comparable to that of lobectomy and sublobar resection In patients not amenable to lobectomy, SABR is an alternative treatment comparable to sublobar resection Chen et al [48] Iguchi et al [49] (2020) (Japan) Retrospective observational study (level 3)…”

Section: Sublobar Resection and Sabr In Nodules Detected During Lung mentioning

confidence: 98%

“…Iguchi et al [49] published a single-center retrospective evaluation of the results of 3 modalities in stage I NSCLC (i.e., radiofrequency ablation, SABR, and SLR). SLR has achieved longer survival, but after adjustment, only reduce HR of disease progression and death of any cause were observed (P = 0.038).…”

Section: Sublobar Resection and Sabr In Operable Stage I Nsclcmentioning

confidence: 99%

See 1 more Smart Citation

Sublobar minimally invasive surgery vs. stereotactic ablative radiotherapy for early stage non-small cell lung cancer

Gálvez¹,

Bolufer²,

Corcoles³

et al. 2020

Mini-invasive Surg

View full text Add to dashboard Cite

Although lobectomy has been traditionally considered the standard treatment for early stage non-small cell lung cancer (NSCLC), lung-sparing resections usually called “sublobar resections” have exponentially increased in their use in the age of minimally-invasive surgery. Sublobar resection, especially anatomical segmentectomy, has shown comparable oncological outcomes in tumors less than 2 cm in diameter without nodal involvement and distant metastasis. On the other hand, more advanced radiation techniques such as stereotactic ablative radiotherapy, have shown excellent local control rates in stage I NSCLC, with low rates of post-treatment complications, so not only is its role growing in inoperable patients, but also in standard-risk stage I patients. There is a need for multicenter randomized trials addressing specifically this issue. This review aims to collect comparative data about the outcomes of both treatment strategies in early stage NSCLC.

show abstract

Section: Sublobar Resection and Sabr In Nodules Detected During Lung mentioning

confidence: 98%

Section: Sublobar Resection and Sabr In Operable Stage I Nsclcmentioning

confidence: 99%

Sublobar minimally invasive surgery vs. stereotactic ablative radiotherapy for early stage non-small cell lung cancer

Gálvez¹,

Bolufer²,

Corcoles³

et al. 2020

Mini-invasive Surg

View full text Add to dashboard Cite

show abstract

“…Two studies reported the duration of postoperative hospitalization for treated patients [11,13]. The pooled duration of postoperative hospitalization was signi cantly lower in the ablation group relative to the SR group (MD: 5.93; 95% CI: 0.78-11.07, P = 0.02, Fig.…”

Section: Duration Of Postoperative Hospitalizationmentioning

confidence: 99%

“…In stage I NSCLC patients with tumors ≤ 2 cm in size, SR yields similar survival outcomes to lobectomy [5,6]. However, 20-30% of stage I NSCLC patients are unable to undergo SR owing to their poor performance status [10][11][12][13][14][15][16][17]. In these patients, percutaneous ablation represents the most minimally invasive treatment strategy [10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Sublobar Resection Versus Ablation for Stage I Non-Small-Cell Lung Cancer: A Meta-Analysis

Yang

Huang³

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundStage I non-small-cell lung cancer (NSCLC) can be treated by both ablation and sublobar resection (SR). This meta-analysis was therefore designed to better compare the relative safety and efficacy of these two approaches to treating stage I NSCLC.Materials and MethodsRelevant studies published through November 2020 in the Cochrane Library, Embase, and PubMed databases were identified for analyses which were conducted with RevMan v5.3. ResultsIn total, 816 potentially relevant articles were identified, of which 8 were ultimately included in the final meta-analysis. Patients in the SR group exhibited a signficantly lower pooled local recurrence (LR) rate (5.0% vs. 25.4%, P < 0.0001), although pooled distant recurrence (DR) rates were similar in both groups (25.7% vs. 23.1%, P = 0.75). The pooled hazard ratio (HR) for overall survival (OS) (HR: 1.23; 95% CI: 1.13-1.33, P < 0.00001), progression-free survival (PFS) (HR: 1.34; 95% CI: 1.15-1.55, P = 0.0002), and cancer-specific survival (CSS) (HR: 1.39; 95% CI: 1.15-1.70, P = 0.0009) all indicated better survival outcomes among patients that underwent HR treatment, while pooled complication rates were similar in both groups (27.7% vs. 43.8%, P = 0.27). Patients that underwent ablation exhibited significantly shorter pooled post-operative hospitalization relative to those in the SR group (MD: 5.93; 95% CI: 0.78-11.07, P = 0.02). No evidence of publication bias was detected through funnel plot analyses.ConclusionsSR treatment of stage I NSCLC patients was associated with a lower LR rate and longer survival as compared to ablation.

show abstract

“…Patients with early-stage NSCLC treated with radiofrequency ablation experienced a significant increase in overall survival. 7 However, Iguchi et al 8 suggested that the 5-year overall and progression-free survival rates were 58.9% and 39.9%, respectively, for radiofrequency ablation; 85.5% and 75.9%, respectively, for sublobar resection in patients with clinical stage I NSCLC. Recently, the emerging molecular targeting therapy has helped to control lung cancer, but its long-term survival rate is limited and expensive.…”

Section: Seed Brachytherapy Combined With Single-agent Chemotherapymentioning

confidence: 99%

<p><sup>125</sup>I Seed Brachytherapy Combined with Single-Agent Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer in the Elderly: A Valuable Solution</p>

Yue¹,

Xing²

2020

OTT

View full text Add to dashboard Cite

The aim of this study was to compare the effectiveness and safety of CT-guided 125 I seed brachytherapy combined with single-agent chemotherapy versus combined chemotherapy in the treatment of elderly NSCLC. Materials and Methods: We retrospectively analyzed 110 patients (64 men and 46 women; mean age=71.25±7.14 years) who were diagnosed with NSCLC without distant metastases between January 2015 and May 2020. A total of 50 patients received 125 I brachytherapy combined with single-agent chemotherapy (group A), whereas 60 patients received combined chemotherapy (group B). The response to therapy and adverse effect were compared between groups. The local response rate was evaluated by CT. Progression-free survival (PFS) and overall survival (OS) data were obtained through clinical follow-up. Results: All patients had been treated and were followed-up for 3-60 months. The median OS and PFS were 23.71±1.41 months (95% CI=20.95-26.47) vs 16.12±0.93 months (95% CI=14.31-17.93) (P<0.05) and 15.08±0.85 months (95% CI=13.42-16.74) vs 10.03±0.53 months (95% CI=9.01-11.06) (P<0.05) in group A and group B, respectively. The local response rate and clinical symptoms of patients in group A were significantly relieved when compared with group B. Severe complications were not observed in either group. Conclusion: CT-guided 125 I seed brachytherapy combined with single-agent chemotherapy is an effective and safe therapy and shows promising results compared to combined chemotherapy alone for NSCLC in the elderly. A randomized study will be needed to assess the superiority of this combined modality treatment.

show abstract

Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non–Small-Cell Lung Cancer: A Single-Center Evaluation

Cited by 23 publications

References 30 publications

Sublobar minimally invasive surgery vs. stereotactic ablative radiotherapy for early stage non-small cell lung cancer

Sublobar minimally invasive surgery vs. stereotactic ablative radiotherapy for early stage non-small cell lung cancer

Sublobar Resection Versus Ablation for Stage I Non-Small-Cell Lung Cancer: A Meta-Analysis

<p><sup>125</sup>I Seed Brachytherapy Combined with Single-Agent Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer in the Elderly: A Valuable Solution</p>

Contact Info

Product

Resources

About